Increased systemic exposure of fimasartan, an angiotensin ii receptor antagonist, by ketoconazole and rifampicin

Journal of Clinical Pharmacology

Volumn 53, Issue 1, 2013, Pages 75-81

  Kim, Jung Won ^a   Yi, SoJeong ^a   Kim, Tae Eun ^a   Lim, Kyoung Soo ^a   Yoon, Seo Hyun ^a   Cho, Joo Youn ^a   Lee, Min Goo ^b   Song, Im Sook ^c   Shin, Sang Goo ^a   Jang, In Jin ^a   Yu, Kyung Sang ^a  

^a Seoul National University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Inje University   (South Korea)

Author keywords

Clinical pharmacology; Clinical research; Drug information; Hypertension; Pharmacokinetics and drug metabolism

Indexed keywords

'SPIKE'; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; FIMASARTAN; KETOCONAZOLE; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NORMAL HUMAN; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AREA UNDER CURVE; BIPHENYL COMPOUNDS; CELLS, CULTURED; CROSS-OVER STUDIES; DRUG INTERACTIONS; HUMANS; KETOCONAZOLE; MALE; OOCYTES; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS; PYRIMIDINES; RIFAMPIN; TETRAZOLES; XENOPUS LAEVIS; YOUNG ADULT;

EID: 84877863054     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011433328     Document Type: Article

References (24)

1. Yi S, Kim TE, Yoon SH, et al. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers. J Cardiovasc Pharmacol . 2011 ;57:682-689.
2. Shin KH, Kim TE, Kim SE, et al. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers. J Cardiovasc Pharmacol . 2011 ;58:492-499.
3. Yi S, Kim JW, Kim TE, et al. Effect of multiple doses of fimasartan, an angiotensin II receptor antagonist, on the steady-state pharmacokinetics of digoxin in healthy volunteers. Int J Clin Pharmacol Ther . 2011 ;49:321-327.
4. Lane A, Engmann E, Bryson S, Lee J, Tan H, Chi Y. Single dose pharmacokinetics (PK) and pharmacodynamics (PD) of BR-A-657, an angiotensin II (AII) antagonist. Clin Pharmacol Ther . 2005;77:P59.
5. Lane A, Kleinermanns D, Bryson S, et al. Multiple dose pharmacokinetics (PK) and pharmacodynamics (PD) of BR-A-657, an angiotensin II (AII) antagonist. Clin Pharmacol Ther . 2005;77:P58.
6. Greenblatt DJ, Wright CE, von Moltke LL, et al. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clin Pharmacol Ther . 1998;64:237-247.
7. Oo C, Chen YC. The need for multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study. J Clin Pharmacol . 2009 ;49:368-369; author reply 370.
8. Choi MK, Jin QR, Choi YL, et al. Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions. Biopharm Drug Dispos . 2011 ;32:175-184.
9. Lam JL, Shugarts SB, Okochi H, Benet LZ. Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. J Pharmacol Exp Ther . 2006;319:864-870.
10. Niemi M, Kivisto KT, Diczfalusy U, et al. Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenet Genomics . 2006 ;16:565-568.
11. van Giersbergen PL, Treiber A, Schneiter R, Dietrich H, Dingemanse J. Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin Pharmacol Ther . 2007 ;81:414-419.
12. Bidstrup TB, Stilling N, Damkier P, et al. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol . 2004 ;60:109-114.
13. Xiong H, Carr RA, Locke CS, et al. Dual effects of rifampin on the pharmacokinetics of atrasentan. J Clin Pharmacol . 2007 ;47: 423-429.
14. Food and Drug Administration (FDA). Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling . Rockville, MD: FDA; 2006.
15. Park JY, Kim KA, Shin JG, Lee KY. Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. Br J Clin Pharmacol . 2004 ;58:397-402.
16. Deng JW, Shon JH, Shin HJ, et al. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin. Pharm Res . 2008 ;25:1807-1814.
17. Fattinger K, Cattori V, Hagenbuch B, Meier PJ, Stieger B. Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology . 2000 ;32:82-86.
18. Johnson BM, Adams LM, Zhang K, et al. Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist. J Clin Pharmacol . 2010 ;50:951-959.
19. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther . 1999 ;66:461-471.
20. Winchell GA, Mistry GC, Kari PP, et al. The effect of ketoconazole on the pharmacokinetics of a selective alpha(1A)-adrenoceptor antagonist. J Clin Pharmacol . 2005 ;45:699-703.
21. Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther . 2003 ;304:223-228.
22. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology . 2002 ;36:164-172.
23. Hatorp V, Hansen KT, Thomsen MS. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. J Clin Pharmacol . 2003 ;43:649-660.
24. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivisto KT. Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther . 2000 ;68:495-500.